The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a potent therapeutic option for the management of obesity, demonstrating exceptional efficacy in several large-scale clinical trials. Despite their promising therapeutic outcomes, the rising popularity of these agents raises signi...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI AG
2024-11-01
|
| シリーズ: | Pharmacoepidemiology |
| 主題: | |
| オンライン･アクセス: | https://www.mdpi.com/2813-0618/3/4/25 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|